CRSP
Price
$45.75Alerts
Change
+$0.60 (+1.33%)
Updated
Nov 11 closing price
Capitalization
4.84B
97 days until earnings call
Intraday BUY SELL Signals
GYRE
Price
$4.26Alerts
Change
+$0.03 (+0.71%)
Updated
Nov 11 closing price
Capitalization
504.72M
139 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRSP vs GYRE

CRSP vs GYRE Comparison Chart in %
View a ticker or compare two or three
VS
CRSP vs. GYRE commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and GYRE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRSP with price predictions
Nov 10, 2026

CRSP in +5.42% Uptrend, advancing for three consecutive days on October 29, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 81 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 37 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (3.498). P/E Ratio (-10.631) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. CRSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for GYRE with price predictions
Nov 10, 2026

GYRE sees MACD Histogram crosses below signal line

GYRE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 37 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GYRE as a result. In 76 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

GYRE moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for GYRE entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GYRE's RSI Oscillator exited the oversold zone, 31 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +16.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.676) is normal, around the industry mean (3.498). P/E Ratio (-23.800) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
CRSP vs GYRE: Fundamental Ratings
CRSP
GYRE
OUTLOOK RATING
1..100
1364
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
9
Undervalued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
6984
P/E GROWTH RATING
1..100
5498
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GYRE's Valuation (9) in the null industry is in the same range as CRSP (24) in the Biotechnology industry. This means that GYRE’s stock grew similarly to CRSP’s over the last 12 months.

GYRE's Profit vs Risk Rating (98) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that GYRE’s stock grew similarly to CRSP’s over the last 12 months.

GYRE's SMR Rating (95) in the null industry is in the same range as CRSP (96) in the Biotechnology industry. This means that GYRE’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's Price Growth Rating (69) in the Biotechnology industry is in the same range as GYRE (84) in the null industry. This means that CRSP’s stock grew similarly to GYRE’s over the last 12 months.

CRSP's P/E Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for GYRE (98) in the null industry. This means that CRSP’s stock grew somewhat faster than GYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPGYRE
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 14 days ago
82%
Bullish Trend 15 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CRSP: $45.15 vs. GYRE: $4.23)
Brand notoriety: CRSP and GYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 253% vs. GYRE: 72%
Market capitalization -- CRSP: $4.84B vs. GYRE: $504.72M
CRSP [@Biotechnology] is valued at $4.84B. GYRE’s [@Biotechnology] market capitalization is $504.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 1 FA rating(s) are green while GYRE’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 1 green, 4 red.
  • GYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, CRSP is a better buy in the long-term than GYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 3 TA indicator(s) are bullish while GYRE’s TA Score has 4 bullish TA indicator(s).

  • CRSP’s TA Score: 3 bullish, 6 bearish.
  • GYRE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, GYRE is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а -9.68% price change this week, while GYRE (@Biotechnology) price change was -4.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 16, 2027.

GYRE is expected to report earnings on Mar 30, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with ABOS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-9.03%
ABOS - GYRE
53%
Loosely correlated
-2.95%
PMN - GYRE
44%
Loosely correlated
-1.73%
PTHS - GYRE
41%
Loosely correlated
-5.02%
CRSP - GYRE
39%
Loosely correlated
-9.77%
SPRC - GYRE
38%
Loosely correlated
-8.78%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RESM23.55-0.08
-0.34%
Columbia Research Enhanced Small Cap ETF (RESM)
BASG27.70-0.16
-0.56%
Brown Advisory Sustainable Growth ETF (BASG)
SPRX33.32-0.28
-0.83%
Spear Alpha ETF (SPRX)
EMSF34.14-0.30
-0.86%
Matthews Emerging Markets Sustainable Future Active ETF (EMSF)
BPRE12.20-0.28
-2.24%
Bluerock Private Real Estate Fund